Retatrutide clears fatty liver in 85%+ of patients, cagrilintide posts Phase 3 obesity results, and Lilly investigates GLP-1s for substance use disorders.
Read digest →PBS covers FDA peptide supplement meeting, oral Wegovy approved on OASIS 4 data, and The Guardian editorial slams RFK Jr.'s peptide deregulation.
Read digest →Landmark study links GLP-1s to reduced addiction risk in 600K+ veterans, J&J's ICOTYDE shows durable psoriasis clearance, and tesamorelin gets new formulation.
Read digest →FDA holds first meeting on peptides as supplement ingredients under RFK Jr., Stanford unveils peptide-to-DNA sequencing, and Skeptic Magazine warns of risks.
Read digest →RFK Jr. signals FDA will lift restrictions on ~14 peptides, Lilly and Novo strike MFN pricing deals, and orforglipron outperforms oral semaglutide.
Read digest →Novo Nordisk cuts US list prices ~50% for 2027, retatrutide hits record 28.7% weight loss in Phase 3, and experts propose 10-year GLP-1 cancer trial.
Read digest →FDA approves oral semaglutide pill and higher Ozempic dose, grants survodutide breakthrough designation for MASH, and oral insulin via cyclic peptides advances.
Read digest →Compounded GLP-1 prescriptions rise despite FDA enforcement, PeptideSciences goes dark, and Cleveland Clinic finds most patients avoid dramatic weight regain.
Read digest →